Enterprise record

Immunovant, Inc. logo

Immunovant, Inc.

Public governance Claims and source records for this enterprise.

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:475a2678-8a75-462d-b44c-64017cac3e77Version: public-1As of: unavailable

19 published Claims3 sources

Key Claims

Board and committees

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 30, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

3 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 29, 2026

    Supports 4 claims
    • Legal Name: Immunovant, Inc. · Claim reviewed: Sep 29, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 29, 2026
    • Published Fact: US · Claim reviewed: Sep 29, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 29, 2026

  2. SEC DEF 14A 0001764013-26-000092

    sec def 14a · Source published: Jul 22, 2026 · Retrieved: Sep 6, 2026

    Supports 11 claims
    • Leadership Role: Frank M. Torti: Executive Chairperson of the Board · Claim reviewed: Sep 29, 2026
    • Leadership Role: Andrew Fromkin: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Atul Pande: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Douglas Hughes: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Jacob Bauer: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Robert Susman: Director · Claim reviewed: Sep 29, 2026
    • Leadership Role: Christopher Van Tuyl: Chief Legal Officer and Corporate Secretary · Claim reviewed: Sep 29, 2026
    • Leadership Role: Eric Venker: Chief Executive Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Jay S. Stout: Chief Technology Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Melanie Gloria: Chief Operating Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Tiago Girão: Chief Financial Officer · Claim reviewed: Sep 29, 2026

  3. IMVT DEF 14A executive officers

    sec filing · Source published: Jul 9, 2025 · Retrieved: May 15, 2026

    Supports 4 claims
    • Leadership Role: Eric Venker, M.D., Pharm.D.: Chief Executive Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Jay S. Stout, Ph.D.: Chief Technology Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Michael Geffner, M.D.: Chief Medical Officer · Claim reviewed: Sep 29, 2026
    • Leadership Role: Tiago Girao: Chief Financial Officer · Claim reviewed: Sep 29, 2026